Galderma S.A. announced that it has gained full rights to distribute Restylane, Perlane, Emervel, Sculptra and Dysport from Valeant Pharmaceuticals International, Inc. The expansion into aesthetic and corrective dermatology in the U.S. and Canada completes Galderma's global skin health footprint and extends its leadership in aesthetic medicine worldwide.
"We at Galderma are delighted to bring Restylane, Perlane, Emervel, and Dysport home in the U.S. and Canada as is the case in dozens of countries around the world. Adding Sculptra to our global portfolio allows us to bring additional indications to our broad range of medical solutions for people with skin needs," said Humberto C. Antunes, CEO and President of Galderma worldwide. "Our science-based approach to fillers and muscle relaxants takes our solutions beyond the aesthetic level to an integral part of holistic medicine, where maintaining, preserving and restoring the health of the skin is as important and as relevant as treating or correcting conditions. With Restylane, Perlane, and Dysport, as well as the innovations to come, we complement our line of prescription and self-medication products to give physicians an arsenal of effective solutions," added Antunes.
Two of Galderma's most recent innovations in the field, Emervel Classic and Emervel Deep, have been submitted for approval by the FDA and Health Canada and are currently under review.
"The U.S. and Canada represent more than 50 percent of the fast growing global medical aesthetics markets," said Stuart Raetzman, Vice President of Galderma for North America. "Demographics, social and cultural drivers, as well as an improving economy, make this an ideal time for Galderma to expand its geographic footprint in aesthetic and corrective medicine to the United States and Canada. At Galderma, people come first. We are thrilled to take on board the experienced teams from Valeant Aesthetics and, more than ever, our intent is to preserve the quality of the long-lasting relationships built with doctors. We look forward to partnering with healthcare providers in the growth and expansion of aesthetic and corrective medicine in North America and advancing the care and treatment of patients." Galderma will pursue to distribute the acquired products through the existing distribution partner. Healthcare practitioners are invited to continue to order products through their current account number and phone numbers. Beginning July 28, Galderma will have a new branded distribution process. All accounts will automatically receive a new Galderma account number and information on the new ordering process.
"This agreement reinforces Galderma's long-term commitment to meet physician and patient needs worldwide. Our high level of investment in Research & Development allows us to continue to develop new products and to bring innovation with the highest standards of clinical safety and efficacy," added Antunes. "This expansion demonstrates Galderma's sole focus on dermatology and skin health and its ongoing dedication to research and innovation."